The size of the global cell counting market is estimated to worth USD 1.18 billion in 2021. This value is forecasted to be growing at a CAGR of 6.87% to reach USD 1.64 billion by 2026.
Cell counting is a counting method for medical applications and plays an essential role in research and clinical activities. The number of cells in liquid media is expressed in cells per unit volume or concentration. Many treatment procedures require cell counts to perform additional procedures. Cell counting is one of the most frequently performed diagnostic and research laboratories in biotechnology, pharmacy, and medicine. Cells can be counted in manual or automatic cell counters. Automated cell counters are designed to solve the problems of manual cell counting.
Cell counters play an essential role in determining the concentration of blood cells, the presence of pathogens, the toxic effect of certain drugs on model cells, and many more. The number of cells is expressed as the number of cells per unit volume in a liquid medium. Various cell count products are instruments, consumables, spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Cell counting is used in multiple applications, such as research institutes, hospitals, diagnostic laboratories, pharmaceutical, biotechnology companies, etc.
The significant factors driving the growth of the global cell counting market are the increasing incidence of cancer and AIDS, corporate and government funding for cell research, and improved IT solutions and better analytical instruments for a picture.
Factors that are increasing the cell counting market emphasize cell counting in the diagnosis and treatment of life-threatening diseases such as cancer and a wide range of cell counting applications. For example, according to the American Cancer Society, nearly 1,688,820 new cancer cases are expected in 2018 in the United States, and approximately 621,840 deaths. Besides, increased "direct" spending and the use of new cell counting technologies have led to the market's growth.
The increasing prevalence of infectious diseases such as sepsis, malaria, influenza, measles, cholera, vector-borne diseases, chikungunya, polio, etc., increases the demand for cell counting methods for diagnosis, which in turn can increase the overall number of cells grown in the device market. According to the World Health Organization (WHO), in 2018, around 241 million people were infected with malaria in approximately 88 countries, and about 442,200 died from malaria. According to the same source, in 2018, the African region had the highest cases, around 99.6% of malaria infection, due to Plasmodium falciparum, followed by the Western Pacific with 72.4% and the Eastern Mediterranean with 68%. Due to Plasmodium vivax, malaria infection was dominant in the North American region, with 72.5% of cases in 2018. Hence, this factor is expected to positively influence the growth of the global cell counting devices market.
Some factors hamper the growth of the cell counting market, such as the high cost of cell analysis, the lack of highly skilled professionals, and the lack of adequate research infrastructure, especially in developing and underdeveloped countries.
Impact of COVID-19 on the global cell counting market:
The unprecedented outbreak of covid-19 has affected the different markets in production and manufacturing, and distribution during the first half of 2020. The life sciences markets have been negatively impacted. Biopharmaceutical innovators are leading the human reaction to the covid-19 pandemic. Major pharmaceutical companies are researching the SARS-COV-2 genome and developing a vaccine to combat the disease.
However, the cell counting market had experienced little growth decline during the first quarter of 2020, as the proliferation of Coronavirus has led to the nationwide lockdown. The high impact rendering factor is the increase in the prevalence of chronic diseases that require next-generation therapeutics; this upsurge has resulted in intensive research efforts that necessitate specialized cell counting instruments. The counting instruments supply chain had been disrupted due to the ban on transportation. The cell counting activities had partially been disrupted owing to the stringent government guidelines. However, significant biopharmaceutical companies and medical institutes have been working toward identifying the virus genome and how it affects the human body. Few tests have shown that some patients with COVID-19 have higher white blood cell and neutrophil levels and lower lymphocyte production. According to other research, the neutrophil-to-lymphocyte ratio can be used as a biomarker to predict the outcome of an infection.
Market Size Available
2021 to 2026
2021 to 2026
By Product, Consumables, End User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This research report on the global cell counting market has been segmented and sub-segmented based on the product, consumables, end-user, and region.
Cell Counting Market - By Product:
The spectrophotometers segment accounted for the market's largest share based on the product due to the enhanced data visualization and analysis software.
Cell Counting Market – By Consumables:
Cell Counting Market – By End User:
Cell Counting Market – By Region:
Regionally, North America accounted for the largest share in 2019 due to the rise in the aging population, high investments by the government in the healthcare sector, and large companies in this area.
North America is anticipated to dominate the overall cell counting market during the forecast period. The central part is mainly due to a larger group of patients and the increase in the geriatric population. In the North American region, the United States holds the largest market share due to the growing number of chronic diseases and an increasing number of research and development programs. According to the latest estimates from the Centers for Disease Control and Prevention, 38,741 people were diagnosed with HIV in the United States in 2019. According to statistics, many patients and the high disposable income have driven market growth in the region.
South America is the second-largest market for cell counting, with growth driven by improved diagnostic and treatment methods that support growing demand in this market. Improved technology in the manufacture of cell counting instruments further enhances the development of this market.
The Asia Pacific is the fastest-growing cell counting market due to continuously developing economies such as India and China and a huge patient population. Supportive government policies, such as reducing excise and customs duties followed by exemptions from the service tax, will stimulate market growth. Also, the increase in healthcare spending is boosting the market in the region.
Japan accounts for the largest market share in the Asia-Pacific cell counting market in 2017. Market growth is attributed to the development of medical devices in addition to research and development activities. Besides, the major market players are involved in exporting medical devices by targeting developing markets to gain a reasonable market share.
India is considered to be the fastest-growing market for medical equipment manufacturers. In India, the cell count market is growing due to cheap raw materials, better access to labor, and an increasing number of hospitals and healthcare facilities. India is one of the top destinations for medical tourism, especially for orthopedic surgeries, which further influences the market's growth.
KEY MARKET PARTICIPANTS:
Companies dominating the global cell counting market profiled in the report are Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Bio-Rad Laboratories, Merck Millipore, Inc., GE Healthcare, Becton, Dickinson and Company, and PerkinElmer, Inc.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
22.214.171.124 Cell Counters
126.96.36.199.1 Automated Cell Counters
188.8.131.52.2 Hemocytometers and Manual Cell Counters
184.108.40.206 Hematology Analysers
220.127.116.11.1 Single-Mode Readers
18.104.22.168.2 Multi-Mode Readers
22.214.171.124 Flow Cytometer
126.96.36.199 Assay Kits
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2.2 Pharmaceutical & Biotechnology Industries
5.2.3 Hospitals & Diagnostic Laboratories
5.2.4 Research & Academic Institutes
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By End-user
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By End-user
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By End-user
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific, Inc.,
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Danaher Corporation
8.3 Agilent Technologies
8.4 Bio-Rad Laboratories
8.5 Merck Millipore, Inc.,
8.6 GE Healthcare
8.7 Becton, Dickinson and Company
8.8 PerkinElmer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures